PE/VC  Aisling Capital

http://www.aislingcapital.com





     Office Locations:

888 Seventh Avenue, 12th Floor
New York, NY 10106
Phone: 212-651-6380
Fax: 212-651-6379

 

Stages:

  • Early
  • Expansion
  • Growth
  • Middle Market


 

Industries:

  • Life Sciences & Healthcare
  • Medical Device

  •  

    Description:

    Aisling Capital is a leading private equity fund that invests in products, technologies, and global businesses that advance health. In particular, the firm seeks companies with promising products in clinical development, or marketed products or services with growth potential. In many cases, Aisling Capital identifies therapeutic and technological areas of interest and then seeks investment opportunities in the leading companies in the target sector. Aisling Capital typically makes investments in healthcare companies that require $20-50 million or more in new capital. The size of the investment is contingent upon the company's stage of development, funding needs and risk profile.


     

    Funds:


      Fund Name


      Amount


      Date

    Get funds under management for this firm including Fund name, Dollar size of fund raise, and Vintage with a National Database subscription or New York Database subscription.



    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
       
       
       
    COMPANY STAGEREVENUE
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Revenue
    Growth Stage
    (also called Mid-stage)
    $2M-$7M
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B
       
       
     

    Investment Team:


    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription or New York Database subscription.
    Aftab Kherani M.D. Partner
    Andrew Schiff Managing Partner
    Ayman Sabi Partner
    Dennis Purcell Senior Adviser, Founder
    Dov A. Goldstein Managing Partner

     

    Recent Funding Events (trailing 12 months):


      Date


      Name


      State


      Amount


      Stage


      03/31/2017


      Promentis Pharmaceuticals


      WI


      $26,000,000


      Series C


     

    Portfolio companies include:


      Agile Therapeutics
        web link


      Ambit Biosciences
        web link


      Aragon Pharmaceuticals
        web link


      Cidara Therapeutics
        web link


      Cytos Biotechnology
        web link


      Dermira
        web link


      Durata Therapeutics
        web link


      Esperion Therapeutics
        web link


      LENSAR
        web link


      Loxo Oncology
        web link


      Miramar Labs
        web link


      Pernix Therapeutics
        web link


      PowerVision
        web link


      PreCision Dermatology
        web link


      Promentis Pharmaceuticals
        web link


      Roka Bioscience
        web link


      Spirox
        web link


      Syros Pharmaceuticals
        web link


      T2 Biosystems
        web link


      TransEnterix
        web link


      Versartis
        web link


      Zavante Therapeutics
        web link


      Zeltiq
        web link


     

    Recent News: